PT  - JOURNAL ARTICLE
AU  - Bizzarri, D.
AU  - Reinders, M.J.T.
AU  - Beekman, M.
AU  - Slagboom, P.E.
AU - BBMRI-NL
AU  - van den Akker, E.B.
TI  - <sup>1</sup>H-NMR metabolomics-based surrogates to impute common clinical risk factors and endpoints
AID  - 10.1101/2021.07.19.21258470
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.07.19.21258470
4099  - http://medrxiv.org/content/early/2021/07/22/2021.07.19.21258470.short
4100  - http://medrxiv.org/content/early/2021/07/22/2021.07.19.21258470.full
AB  - Missing or incomplete phenotypic information can severely deteriorate the statistical power in epidemiological studies. High-throughput quantification of small-molecules in bio-samples, i.e. ‘metabolomics’, is steadily gaining popularity, as it is highly informative for various phenotypical characteristics. Here we aim to leverage metabolomics to impute missing data in clinical variables routinely assessed in large epidemiological and clinical studies. To this end, we have employed ∼25,000 1H-NMR metabolomics samples from 28 Dutch cohorts collected within the BBMRI-NL consortium, to create 19 metabolomics-based predictors for clinical variables, including diabetes status (AUC5-Fold CV = 0.94) and lipid medication usage (AUC5-Fold CV = 0.90). Subsequent application in independent cohorts confirmed that our metabolomics-based predictors can indeed be used to impute a wide array of missing clinical variables from a single metabolomics data resource. In addition, application highlighted the potential use of our predictors to explore the effects of totally unobserved confounders in omics association studies. Finally, we show that our predictors can be used to explore risk factor profiles contributing to mortality in older participants. To conclude, we provide 1H-NMR metabolomics-based models to impute clinical variables routinely assessed in epidemiological studies and illustrate their merit in scenarios when phenotypic variables are partially incomplete or totally unobserved.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was performed within the framework of the BBMRI Metabolomics Consortium funded by BBMRI-NL (a research infrastructure financed by the Dutch government, NWO 184.021.007 and 184.033.111), by X-omics (NWO 184.034.019), VOILA (ZonMW 457001001) and Medical Delta (scientific program METABODELTA: Metabolomics for clinical advances in the Medical Delta). EvdA is funded by a personal grant of the Dutch Research Council (NWO; VENI: 09150161810095). A full list of acknowledgements for all the contributing studies is following: ALPHAOMEGA Financial support for the Alpha Omega Cohort was obtained from the Dutch Heart Foundation (grant 200T401) and the National Institutes of Health (grant R01HL076200), USA. DNA isolation was funded by BBMRI-NL (grant CP2011-18). AMSTERDAM DEMENTIA COHORT: Research within the VUmc Alzheimer center is part of the neurodegeneration research program of Amsterdam Neuroscience supported by Alzheimer Nederland and Stichting VUmc fonds. LUMINA: LUMINA (i.e. its subcohorts CHARM, CSF, MRS) is supported by grants obtained from the Netherlands Organization for the Health Research and Development (ZonMw; no. 90700217) and VIDI (ZonMw; no. 91711319); the Netherlands Organisation for Scientific Research (NWO) VICI (no.918.56.602) and Spinoza prize (2009) grants; the Centre for Medical Systems Biology (CMSB) and Netherlands Consortium for Systems Biology (NCSB), both within the framework of the Netherlands Genomics Initiative (NGI)/Netherlands Organization for Scientific Research (NWO) the 7th Framework EU project EUROHEADPAIN (no. 602633). CHECK: CHECK was funded by the Dutch Arthritis Association on the lead of a steering committee comprising 16 members with expertise in different fields of OA, chaired by Professor JWJ Bijlsma and coordinated by J Wesseling. Involved are: Erasmus Medical Center Rotterdam; Kennemer Gasthuis Haarlem; Leiden University Medical Center; Maastricht University Medical Center; Martini Hospital Groningen/Allied Health Care Center for Rheumatology and Rehabilitation Groningen; Medical Spectrum Twente Enschede/Ziekenhuisgroep Twente Almelo; Reade, formerly Jan van Breemen Institute/VU Medical Center Amsterdam; St. Maartenskliniek Nijmegen; University Medical Center Utrecht, and Wilhelmina Hospital Assen. CODAM: Part of this work was supported by grants of the Netherlands Organisation for Scientific Research (940-35-034) and the Dutch Diabetes Research Foundation (98.901). THE MAASTRICHT STUDY (TMS): This study was supported by the European Regional Development Fund via OP-Zuid, the Province of Limburg, the Dutch Ministry of Economic Affairs (grant 31O.041), Stichting De Weijerhorst (Maastricht, the Netherlands), the Pearl String Initiative Diabetes (Amsterdam, the Netherlands), CARIM School for Cardiovascular Diseases (Maastricht, the Netherlands), Stichting Annadal (Maastricht, the Netherlands), Health Foundation Limburg (Maastricht, the Netherlands) and by unrestricted grants from Janssen-Cilag B.V. (Tilburg, the Netherlands), Novo Nordisk Farma B.V. (Alphen aan den Rijn, the Netherlands) and Sanofi-Aventis Netherlands B.V. (Gouda, the Netherlands).THE HOORN DIABETES CARE SYSTEM COHORT STUDY (DCS): This study was been made possible by collaboration with the Diabetes Care System West-Friesland. The authors thank participants of this study and research staff of the Diabetes Care System West-Friesland. ERASMUS RUCPHEN FAMILY (ERF) STUDY:The Erasmus Rucphen Family (ERF) study has received funding from the Centre for Medical Systems Biology (CMSB) and Netherlands Consortium for Systems Biology (NCSB), both within the framework of the Netherlands Genomics Initiative (NGI)/Netherlands Organization for Scientific Research (NWO). ERF study is also a part of EUROSPAN (European Special Populations Research Network) (FP6 STREP grant number 18947 (LSHG-CT-2006-018947)); European Network of Genomic and Genetic Epidemiology (ENGAGE) from the European Community's Seventh Framework Programme (FP7/2007-2013)/grant agreement HEALTH-F4-2007-201413; "Quality of Life and Management of the Living Resources" of 5th Framework Programme (no. QLG2-CT-2002-01254); FP7 project EUROHEADPAIN (nr 602633), the Internationale Stichting Alzheimer Onderzoek (ISAO); the Hersenstichting Nederland (HSN); and the JNPD under the project PERADES (grant number 733051021, Defining Genetic, Polygenic and Environmental Risk for Alzheimer Disease using multiple powerful cohorts, focused Epigenetics and Stem cell metabolomics). Metabolomics measurements of ERF has been funded by Biobanking and Biomolecular Resources Research Infrastructure (BBMRI)-NL (184.021.007). The ERF-follow up study is funded by CardioVasculair Onderzoek Nederland (CVON 2012-03). We are grateful to all study participants and their relatives, general practitioners and neurologists for their contributions and to P. Veraart for her help in genealogy, J. Vergeer for the supervision of the laboratory work, both S.J. van der Lee and A. van der Spek for collection of the follow-up data and P. Snijders for his help in data collection of both baseline and follow-up data. ROTTERDAM STUDY: The Rotterdam Study is supported by the Erasmus MC University Medical Center and Erasmus University Rotterdam; The Netherlands Organisation for Scientific Research (NWO); The Netherlands Organisation for Health Research and Development (ZonMw); the Research Institute for Diseases in the Elderly (RIDE); The Netherlands Genomics Initiative (NGI); the Ministry of Education, Culture and Science; the Ministry of Health, Welfare and Sports; the European Commission (DG XII); and the Municipality of Rotterdam. The authors are grateful to the study participants, the staff from the Rotterdam Study and the participating general practitioners and pharmacists. Metabolomics measurements were funded by Biobanking and Biomolecular Resources Research Infrastructure (BBMRI) NL (184.021.007) and the JNPD under the project PERADES (grant number 733051021, Defining Genetic, Polygenic and Environmental Risk for Alzheimers Disease using multiple powerful cohorts, focused Epigenetics and Stem cell metabolomics). GARP: The Leiden University Medical Centre have and are supporting the RAAK and GARP study. This study was supported by the Dutch Arthritis Foundation and Pfizer Groton, Connecticut, USA. We are indebted to drs. N. Riyazi, J. Bijsterbosch, H.M. Kroon and I. Watt for collection of data. HELIUS: The HELIUS study is conducted by the Academic Medical Center Amsterdam and the Public Health Service of Amsterdam. Both organisations provided core support for HELIUS. The HELIUS study is also funded by the Dutch Heart Foundation, the Netherlands Organization for Health Research and Development (ZonMw), the European Union (FP-7), and the European Fund for the Integration of non-EU immigrants (EIF). LIFELINES-DEEP: We thank the participants and staff of the Lifelines cohort for their collaboration, particularly B. Bolmer and S. Gerritsma for coordinating the Lifelines data. We thank J. Dekens and J. Arends for management and technical support. We also thank the Genomics Coordination Center for providing data infrastructure and access to high performance computing clusters. This project was funded by the Netherlands Heart Foundation (IN-CONTROL CVON grant 2012-03 and 2018-27 to A.Z. and J.F.); the NWO Gravitation Exposome-NL (024.004.017) to J.F. and A.Z.; NWO-VIDI 864.13.013 to J.F., NWO-VIDI 016.178.056 to A.Z., and NWO Spinoza Prize SPI 92-266 to C.W.; the European Research Council Consolidate grant 101001678 to J.F., and the RuG Investment Agenda Grant Personalized Health to C.W.. LEIDEN LONGEVITY STUDY (LLS): The LLS has received funding from the European Union's Seventh Framework Programme (FP7/2007-2011) under grant agreement n 259679. This study was supported by a grant from the Innovation-Oriented Research Program on Genomics (SenterNovem IGE05007), the Centre for Medical Systems Biology, and the Netherlands Consortium for Healthy Ageing (grants 05040202 and 050-060-810), all in the framework of the Netherlands Genomics Initiative, Netherlands Organization for Scientific Research (NWO), Unilever Colworth, and by BBMRI-NL, a Research Infrastructure financed by the Dutch government (NWO 184.021.007). NESDA: The infrastructure for the NESDA study (www.nesda.nl) is funded through the Geestkracht program of the Netherlands Organisation for Health Research and Development (ZonMw, grant number 10-000-1002) and financial contributions by participating universities and mental health care organizations (VU University Medical Center, GGZ inGeest, Leiden University Medical Center, Leiden University, GGZ Rivierduinen, University Medical Center Groningen, University of Groningen, Lentis, GGZ Friesland, GGZ Drenthe, Rob Giel Onderzoekscentrum). PROSPECTIVE STUDY OF PRAVASTATIN IN THE ELDERLY AT RISK (PROSPER): The PROSPER study was supported by an investigator initiated grant obtained from Bristol-Myers Squibb. Prof. Dr. J. W. Jukema is an Established Clinical Investigator of the Netherlands Heart Foundation (grant 2001 D 032). PROSPER was supported by the European Federation of Pharmaceutical Industries Associations (EFPIA), Innovative Medicines Initiative Joint undertaking, European Medical Information Framework (EMIF) grant number 115372 and the European Commission under the Health Cooperation Work Programme of the 7th Framework Programme (Grant number 305507) Heart omics in AGEing (HOMAGE). THE LUMC ARTHROPLASTY STUDIES: This was a combination of TACTICS, TOMAAT and RAAK cohorts. TACTICS was funded by The Dutch Board of Health Care Insurances (College voor Zorgverzekeringen; OG99/023) and Sanquin Blood Bank. Involved were Prof. dr R.G.H.H. Nelissen, MD, Prof. dr A. Brand, MD, Leiden University Medical Centre; R.L. te Slaa MD, Reinier de Graaf Gasthuis, Delft; Dr R.G. Poll MD, Slotervaart ziekenhuis, Amsterdam; Dr K.M. Veenstra Franciscus ziekenhuis, Rotterdam and Prof. dr D. van Rhenen Sanquin Blood Bank, Rotterdam. Funding for the TOMAAT-study was received from ZonMW (06-601) and Sanquin Blood Supply (03-002), the Netherlands. Clinical Trial Number: ISRCTN96327523 (controlled-trials.com) and NTR 303 (Dutch Trial Register). The RAAK study was supported by the Leiden University Medical Centre. Furthermore, the molecular studies performed within to the RAAK study has received funding from the Dutch Arthritis Association (DAA_10_1-402), Biobanking and BioMolecular resources Research Infrastructure The Netherlands (BBMRI-NL) complementation project CP2013-84-CP2013-83 and Dutch Scientific Research council NWO /ZonMW VICI scheme (nr. 91816631/528). UCORBIO: UCORBIO is conducted and supported by department of Cardiology, University Medical Center Utrecht, Netherlands. Folkert W. Asselbergs is supported by UCL Hospitals NIHR Biomedical Research Centre. Metabolic profiling was supported by Biobanking and BioMolecular resources Research Infrastructure, the Netherlands (BBMRI-NL). UCORBIO received funding from FP EU project CVgenes@target (HEALTH-F2-2013 601456). We would like to thank Ms. Jonne Hos and Ms. Merel Schurink for their logistical support and Daniel Kofink, PhD, for data management. VUNTR: Funding was obtained from the Netherlands Organization for Scientific Research (NWO) and MagW/ZonMW grants 904-61-090, 985-10-002, 904-61-193,480-04-004, 400-05-717, Addiction-31160008, Middelgroot-911-09-032, Spinozapremie 56-464-14192, Biobanking and Biomolecular Resources Research Infrastructure (BBMRI NL, 184.021.007).; the European Community's Seventh Framework Program (FP7/2007-2013), ENGAGE (HEALTH-F4-2007-201413); the European Science Council (ERC Advanced, 230374), Rutgers University Cell and DNA Repository (NIMH U24 MH068457-06), the Avera Institute, Sioux Falls, South Dakota (USA) and the National Institutes of Health (NIH, R01D0042157-01A, MH081802, Grand Opportunity grants 1RC2 MH089951). We gratefully acknowledge grant NWO 480-15-001/674: Netherlands Twin Registry Repository: researching the interplay between genome and environment.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Studies included in BBMRI-nl have been approved by their respective institutional Medical Ethical Committees. The list of Ethics statements is in the Supplementary Document Table S4: Ethics statements. Here is the full list: Alpha Omega Cohort The protocol of the Alpha Omega Trial, from which the Alpha Omega Cohort emerged, was approved by the Medical Ethics Review Committee of Haga Hospital Leyenburg, The Hague (METC Zuidwest Holland; L01.049) and by local ethics committees of all participating hospitals. In accordance with the Declaration of Helsinki, the Alpha Omega Cohort obtained informed consent from all participants prior to their entering the study. Amsterdam Dementia Cohort The Amsterdam Dementia Cohort study protocol was approved by the Medical Ethics Committee of VU University Medical Centre (2016.061). In accordance with the Declaration of Helsinki, the Amsterdam Dementia Cohort obtained informed consent from all participants prior to their entering the study. BIOMARCS The BIOMarker study to identify the Acute risk of a Coronary Syndrome (BIOMArCS) study protocol was approved by the Medical Ethics Committee of the Erasmus MC (MEC-2007-185). In accordance with the Declaration of Helsinki, the BIOMarker study to identify the Acute risk of a Coronary Syndrome (BIOMArCS) obtained informed consent from all participants prior to their entering the study. LUMINA The study protocols making up the Leiden University MIgraine Neuro-Analysis (LUMINA) cohort were approved by the Medisch Ethische Toetsingcommissie (METC) of the Leiden University Medical Center (LUMC) (registration numbers P07.079 and P12.113). In accordance with the Declaration of Helsinki, the LUMINA CSF, MRS, and CHARM subcohorts obtained informed consent from all participants prior to their entering the study. CHECK Cohort Heup en Cohort Knie study protocol was approved by Medical ethics committees of all participating centres. In accordance with the Declaration of Helsinki, the Cohort Heup en Cohort Knie obtained informed consent from all participants prior to their entering the study. CODAM The Cohort on Diabetes and Atherosclerosis Maastricht (CODAM) study protocol was approved by the Medical Ethics Review Committee of the AzM/UM (MEC 99-112 /MEC05-170). In accordance with the Declaration of Helsinki, the CODAM study btained informed consent from all participants prior to their entering the study The Maastricht Study (TMS) The Maastricht Study protocol was approved by the Medical Ethics Review Committee AzM/UM (NL31329.068.10) and the Minister of Health, Welfare and Sports of the Netherlands (Permit 131088-105234-PG). In accordance with the Declaration of Helsinki, the Maastricht Study obtained informed consent from all participants prior to their entering the study. The Hoorn Diabetes Care System cohort study (DCS) The Hoorn Diabetes Care System Cohort study protocol was approved by the ethical committee VU Vrije Universiteit Medical Center (2007/57). In accordance with the Declaration of Helsinki, the The Hoorn Diabetes Care System Cohort obtained informed consent from all participants prior to their entering the study. Erasmus Rucphen Family (ERF) study The Erasmus Rucphen Family study protocol was approved by the Medical Ethics Committee of the Erasmus MC Rotterdam, the Netherlands (MEC 213.575/2002/114). In accordance with the Declaration of Helsinki, the Erasmus Rucphen Family study obtained informed consent from all participants prior to their entering the study. Rotterdam Study The Rotterdam Study protocol was approved by the Medical Ethics Committee of the Erasmus MC Rotterdam, the Nethrlands. (MEC 02.1015) and by the Dutch Ministry of Health, Welfare, and Sport (Population Screening Act WBO, license number 1071272-159521-PG). In accordance with the Declaration of Helsinki, the Rotterdam Study obtained written informed consent from all participants prior to their entering the study. FUNCTGENOMICS The 500 Functional Genomics study protocol was approved by Commissie Mensgebonden Onderzoek Regio Arnhem-Nijmegen (42561.091.12). In accordance with the Declaration of Helsinki, the 500 Functional Genomics study obtained informed consent from all participants prior to their entering the study. GARP The Genetics, ARthrosis and Progression study protocol was approved by the Medical Ethic Committee of the LUMC (P 76/98). In accordance with the Declaration of Helsinki, the Genetics, ARthrosis and Progression obtained informed consent from all participants prior to their entering the study. HELIUS The HEalthy LIfe in an Uran Society (HELIUS) study protocol was approved by the Medical Ethics Board of the Amsterdam University Medical Centers, location AMC (METC 10/100#10.17.1729). In accordance with the Declaration of Helsinki, the HEalthy LIfe in an Uran Society study obtained informed consent from all participants prior to their entering the study. LIFELINES-DEEP The LifeLines DEEP study was approved by the ethics committee of the University Medical Center Groningen, document number METC UMCG LLDEEP: M12.113965. All participants signed an informed consent form before study enrollment. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Leiden Longevity Study (LLS) The Leiden Longevity Study protocol was approved by the Medical Ethical Committee of the Leiden University Medical Center before the start of the study (P01.113). In accordance with the Declaration of Helsinki, the Leiden Longevity Study obtained informed consent from all participants prior to their entering the study. NESDA The Netherlands Study of Depression and Anxiety (NESDA) was approved by the Medical Ethical Committee of the VUmc (reference number 2003/183). In accordance with the Declaration of Helsinki, the Netherlands Study of Depression and Anxiety obtained informed consent from all participants prior to their entering the study. PROspective Study of Pravastatin in the Elderly at Risk (PROSPER) The Prospective study of Pravastatin in the Elderly at Risk protocol was approved by institutional ethics review boards of centres of Cork University (Ireland), Glasgow University (Scotland) and Leiden University Medical Center (the Netherlands). In accordance with the Declaration of Helsinki, the The Prospective study of Pravastatin in the Elderly at Risk obtained informed consent from all participants prior to their entering the study. The LUMC arthroplasty studies RAAK Research Artrotisch Articulair Kraakbeen study protocol was approved by Medical Ethics Committee of the LUMC (P08.239 and P19.013). In accordance with the Declaration of Helsinki, the Research Artrotisch Articulair Kraakbeen obtained informed consent from all participants prior to their entering the study. TACTICS The 'Kwaliteit van leven en morbiditeit 10 jaar na totale heup of knie vervanging' study protocol was approved by Medical Ethics Committee of the LUMC (P00.179 and P11.050). In accordance with the Declaration of Helsinki, the Kwaliteit van leven en morbiditeit 10 jaar na totale heup of knie vervanging obtained informed consent from all participants prior to their entering the study. TOMAAT The 'Transfusie op maat studie - optimale bloedmanagement bij electieve orthopedische ingrepen' study protocol was approved by Medical Ethics Committee of the LUMC (P03.044). In accordance with the Declaration of Helsinki, the Transfusie op maat studie - optimale bloedmanagement bij electieve orthopedische ingrepen obtained informed consent from all participants prior to their entering the study. STEMI_GIPS-III The Glycometabolic Intervention as Adjunct to Primary Percutaneous Coronary Intervention in ST- Segment Elevation Myocardial Infarction (GIPS) III study is a double-blind placebo-controlled randomized clinical trial and was designed to determine whether metformin preserves left ventricular function after ST-segment elevation myocardial infaction (STEMI) in patients without diabetes. The study protocol was in accordance with the Declaration of Helsinki and was approved by the institutional review board (METC 2010.077, Groningen, the Netherlands) and national regulatory authorities. This trial was registered at clinicaltrials.gov (NCT01217307). UCORBIO Utrecht Coronary Biobank Study (UCORBIO) study protocol was approved by the Medical Ethics Committee of the UMC Utrecht (reference number 11-183). In accordance with the Declaration of Helsinki, the Utrecht Coronary Biobank Study (UCORBIO) obtained informed consent from all participants prior to their entering the study. VUNTR The Netherlands twin Register study protocol was approved by the Central Ethics Committee on Research Involving Human Subjects of the VU University Medical Centre, Amsterdam, an Institutional Review Board certified by the U.S. Office of Human Research Protections (IRB number IRB00002991 under Federal-wide Assurance-FWA00017598. In accordance with the Declaration of Helsinki, the Netherlands Twin Register obtained informed consent from all participants prior to their entering the study. HOF The HOF study Prenatal nutrition and adult disease, an analysis of sib-pairs discordant for exposure to the Dutch famine of 1944-1945 was approved by the Institutional Review Board of Columbia University, New York (IRB-AAAB4053) and by the Medical Ethics Committee of Leiden University Medical Center (P02.082). Written informed consent was obtained from all study participants. STABILITEIT The Amsterdam Dementia Cohort study protocol, from which the STABILITEIT cohort emerged, was approved by the Medical Ethics Committee of VU University Medical Centre (2016.061). In accordance with the Declaration of Helsinki, the Amsterdam Dementia Cohort obtained informed consent from all participants prior to their entering the study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData available upon request at bbmri.nl https://www.bbmri.nl/samples-images-data